Page 35 - 《中国药科大学学报》2025年第4期

第 56 卷第 4 期 廖梦归，等：ASO 的发展、递送与免疫疗法的机遇挑战 431

[42] Stölzel U. Phase 3 trial of RNAi therapeutic givosiran for acute sights into RNA in CSF of pediatric SMA patients after 6
intermittent Porphyria[J]. Z Gastroenterol, 2020, 58(8): 785. months of nusinersen[J]. Biol Direct, 2023, 18(1): 57.
[43] Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the treatment [51] Monine M, Norris D, Wang YF, et al. A physiologically-based
of heterozygous familial hypercholesterolemia[J]. N Engl J pharmacokinetic model to describe antisense oligonucleotide
Med, 2020, 382(16): 1520-1530. distribution after intrathecal administration[J]. J Pharmacokinet
[44] Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of in- Pharmacodyn, 2021, 48(5): 639-654.
clisiran in patients with elevated LDL cholesterol[J]. N Engl J [52] Hoy SM. Nusinersen: first global approval[J]. Drugs, 2017,
Med, 2020, 382(16): 1507-1519.
77(4): 473-479.
[45] Munagala R, Aqil F, Jeyabalan J, et al. Exosome-mediated de-
[53] Full article: Antisense oligonucleotides: absorption, distribution,
livery of RNA and DNA for gene therapy[J]. Cancer Lett, 2021,
metabolism, and excretion[EB/OL]. [2025-06-22]. https://www.
505: 58-72.
tandfonline.com/doi/full/10.1080/17425255.2021.1992382.
[46] Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham
[54] Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen
control in infantile-onset spinal muscular atrophy[J]. N Engl J
treatment for patients with hereditary transthyretin
Med, 2017, 377(18): 1723-1732.
amyloidosis[J]. N Engl J Med, 2018, 379(1): 22-31.
[47] Rinaldi C, Wood MJA. Antisense oligonucleotides: the next
[55] Chen SX, Heendeniya SN, Le BT, et al. Splice-modulating anti-
frontier for treatment of neurological disorders[J]. Nat Rev Neu-
sense oligonucleotides as therapeutics for inherited metabolic
rol, 2018, 14(1): 9-21.
diseases[J]. BioDrugs, 2024, 38(2): 177-203.
[48] Wu YF, Chen JN, Jong YJ. Treating neuromuscular diseases:
unveiling gene therapy breakthroughs and pioneering future ap- [56] Zhou BH, Gao Y, Zhang P, et al. Acquired resistance to im-
plications[J]. J Biomed Sci, 2025, 32(1): 30. mune checkpoint blockades: the underlying mechanisms and
[49] Duan CL, Kang M, Pan XJ, et al. Intrathecal administration of a potential strategies[J]. Front Immunol, 2021, 12: 693609.
novel siRNA modality extends survival and improves motor [57] Tao YW, Tian C, Qi SL, et al. Targeting both death and para-
function in the SOD1 G93A ALS mouse model[J]. Mol Ther Nu- caspase domains of MALT1 with antisense oligonucleotides
cleic Acids, 2024, 35(1): 102147. overcomes resistance to immune-checkpoint inhibitors[J]. Nat
[50] Garofalo M, Bonanno S, Marcuzzo S, et al. Preliminary in- Cancer, 2025, 6(4): 702-717.

专家介绍］朱晨，博士，现任中国科学院杭州医学研究所生物治疗与组学中心王雅俊研究员组博
［
士后。具体研究内容聚焦于以下两个方面：（1）细胞膜表面的糖基化 RNA 的示踪以及其生物学功
能研究。（2）通过蛋白工程化与人工智能辅助的蛋白设计，开发核酸分子的精准生物合成方法。
近五年，在 Journal of Integrative Plant Biology, Nature Communications 等期刊发表学术论文
5 篇。

专家介绍］王雅俊，研究员，博士生导师，中国科学院“百人计划”（2024）、浙江省“海外高层次人
［
才计划”青年项目（2023）资助。现任中国科学院杭州医学研究所生物治疗与组学中心研究员。致
力于化学生物学与合成生物学交叉领域的研究，核心目标是系统探索核酸的化学与生物学特性，
开发核酸分子的大规模、精准生物合成与修饰平台，并推动其在药物研发与生物技术中的应用。
具体研究内容聚焦于以下三个方面：（1）核酸的基础化学生物学研究，涵盖细胞膜表面的糖基化
RNA，含有非天然碱基和糖环结构的功能性核酸、小核酸、mRNA 等；（2）通过蛋白工程化与人工
智能辅助的蛋白设计与进化，开发核酸分子的大规模、精准生物合成与修饰方法，（3）开发基于
DNA、RNA 与 XNA 等多种核酸的功能分子、分子工具与治疗药物，为细胞命运与生物体系调控
及疾病诊断和治疗提供新的策略。近五年，以第一作者和通信作者（含共同）于 Nature Chemistry,
Advanced Materials, Journal of the American Chemical Society, Nature Communications,
Nucleic Acids Research, Chemical Science 等期刊发表研究论文。